Abstract 1010P
Background
B7H7, a novel immune checkpoint, is a promising target in solid tumors due to its overexpression and correlation with poor prognosis. HBM1020 is a first-in-class anti-B7H7 antibody designed to augment T cell anti-tumor response.
Methods
This objective of this phase 1 study is to assess the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of HBM1020 in patients (pts) with advanced solid tumors. In Part 1 (dose escalation), HBM1020 was administered at dose levels between 0.3mg/kg and 30mg/kg every 3 weeks (Q3W) by intravenous infusion. Enrollment is ongoing in Part 2 (dose expansion).
Results
As of 01-April-2024, 17 pts with have received HBM1020 from 0.3mg/kg to 30 mg/kg Q3W. Median age was 62 years (34-80). All pts completed dose limiting toxicity (DLT) observation periods (21 days) and no DLT events were observed and MTD has not yet been reached. A total of 6 (35.3%) pts had a treatment related adverse event (TRAE) and all TRAEs were Grade 1-2. Eleven (64.7%) pts had reported serious adverse events (SAEs) and all SAEs were deemed unrelated to study treatment by both investigator and study sponsor. Nine (9) pts had post baseline tumor evaluation, and 6 out of 9 (66.7%) pts had stable disease (SD) as best response (including 1 pt with SD, tumor shrinkage of 25%). PK analysis of HBM1020 demonstrated a typical IgG behavior with elimination half-life of ∼two weeks in the dose range of 3 to 20 mg/kg. Drug exposure increased in a nearly dose-proportional manner. The expression of B7H7 was assessed by validated immunohistochemistry (IHC) assay for patients with available archived samples.
Conclusions
HBM1020, as a first-in-class anti-B7H7 antibody, demonstrated promising safety and tolerability profiles in patients with advanced solid tumors. Further studies are warranted to explore the therapeutic potential of HBM1020 in solid tumors.
Clinical trial identification
NCT05824663.
Editorial acknowledgement
Legal entity responsible for the study
Harbour Biomed US.
Funding
Harbour Biomed US.
Disclosure
X. Tao: Financial Interests, Personal, Full or part-time Employment: Harbour Biomed Ltd; Financial Interests, Personal, Stocks/Shares: Harbour Biomed Ltd. All authors have declared no conflicts of interest.
Resources from the same session
937P - Pain, fatigue and depression symptom cluster in head and neck cancer survivors
Presenter: Iakov Bolnykh
Session: Poster session 03
938TiP - Phase II TROPHY-IO-HN study of pembrolizumab ±sacituzumab govitecan in first-line recurrent /metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) patients
Presenter: Amanda Psyrri
Session: Poster session 03
941TiP - A phase I/IIa, open-label, dose-finding trial to evaluate safety, immunogenicity, and anti-tumour activity of VB10.16 in combination with pembrolizumab in patients with unresectable recurrent or metastatic HPV16-positive head and neck squamous cell carcinoma (R/M HNSCC)
Presenter: Saira Khalique
Session: Poster session 03
942TiP - A randomized controlled clinical trial of neoadjuvant immunochemotherapy vs up-front surgery in patients with locally advanced resectable oral squamous cell carcinoma (Tophill trial)
Presenter: Laiping Zhong
Session: Poster session 03
Resources:
Abstract
945TiP - JADE: A phase (ph) III study to evaluate dostarlimab vs placebo (PBO) as sequential therapy after chemoradiation (CRT) in patients (pts) with locally advanced unresected head and neck squamous cell carcinoma (LA-HNSCC)
Presenter: Jean-Pascal Machiels
Session: Poster session 03
1002P - A phase Ia study of the myeloid-derived suppressor cell modulator HF1K16 in refractory and metastatic cancer patients: Preliminary efficacy and safety
Presenter: Ruofan Huang
Session: Poster session 03